Aurobindo Pharma

Aurobindo Pharma

AUROPHARMA.NSApproved
Hyderabad, IndiaFounded 1986aurobindo.com

Aurobindo Pharma Limited is a vertically integrated pharmaceutical company founded in 1986, headquartered in Hyderabad, India. The company has established itself as a major player in the global generics market with a diverse portfolio spanning antibiotics, ARVs, CVS, CNS, gastroenterology, and other therapeutic segments. With multiple manufacturing facilities across India, the US, and other countries, Aurobindo has built a robust supply chain and regulatory compliance framework serving both developed and emerging markets.

Market Cap
$8.0B
Founded
1986
Employees
25,000-30,000
Focus
Biotech

AUROPHARMA.NS · Stock Price

USD 1292.00+682.65 (+112.03%)

Historical price data

AI Company Overview

Aurobindo Pharma Limited is a vertically integrated pharmaceutical company founded in 1986, headquartered in Hyderabad, India. The company has established itself as a major player in the global generics market with a diverse portfolio spanning antibiotics, ARVs, CVS, CNS, gastroenterology, and other therapeutic segments. With multiple manufacturing facilities across India, the US, and other countries, Aurobindo has built a robust supply chain and regulatory compliance framework serving both developed and emerging markets.

Technology Platform

Vertically integrated pharmaceutical manufacturing platform specializing in generic drugs, APIs, and complex formulations with strong regulatory compliance capabilities across global markets.

Pipeline Snapshot

6

6 drugs in pipeline, 3 in Phase 3

DrugIndicationStage
Test Product + Reference Product + PlaceboBronchial AsthmaPhase 3
Adapalene 0.1% Gel + Differin 0.1% Topical GelAcne VulgarisPhase 3
Albuterol Sulfate HFA 0.09 mg (Reference) + Albuterol Sulfate HFA 0.18 mg (Refer...Bronchial AsthmaPhase 3
Amphotericin B Liposome + AmBisome (Amphotericin B) LiposomeVisceral LeishmaniasisPhase 1
Amlodipine - reference + Amlodipine ODT - test + Amlodipine ODT - testHealthy VolunteersPhase 1

Funding History

1
IPOUndisclosedUndisclosedJun 15, 1995

FDA Approved Drugs

442
CITALOPRAM HYDROBROMIDEANDAMar 13, 2026
EVEROLIMUSANDAFeb 25, 2026
ARIPIPRAZOLEANDAFeb 18, 2026

Opportunities

Significant growth opportunities exist in complex generics, biosimilars expansion, and emerging market penetration.
The company is well-positioned to benefit from continued patent expiries and increasing global demand for affordable healthcare solutions.

Risk Factors

Key risks include regulatory compliance challenges, intense pricing pressure in generics markets, and potential supply chain disruptions.
Currency fluctuations and competition from other low-cost manufacturers also pose ongoing challenges.

Competitive Landscape

Aurobindo competes in a highly competitive global generics market against companies like Teva, Dr. Reddy's, Sun Pharma, and Cipla. The company differentiates through vertical integration, broad therapeutic portfolio, and strong presence in both developed and emerging markets.

Publications
20
Patents
20
Pipeline
6
FDA Approvals
442

Company Info

TypeTherapeutics
Founded1986
Employees25,000-30,000
LocationHyderabad, India
StageApproved
RevenueRevenue Generating

Trading

TickerAUROPHARMA.NS
ExchangeNSE

Therapeutic Areas

Anti-infectivesCardiovascularCNSGastroenterologyOncologyHIV/AIDSRespiratoryBiosimilars

Partners

Various global pharmaceutical distributorsContract manufacturing partnersResearch collaborators
SIMILAR COMPANIES
Mankind Pharma
Mankind Pharma
Pre-clinical · New Delhi
Sun Pharmaceutical
Sun Pharmaceutical
Pre-clinical ·
Lupin Limited
Lupin Limited
Pre-clinical ·
Dr. Reddy's Laboratories
Dr. Reddy's Laboratories
Pre-clinical · Princeton
Abbott India
Abbott India
Pre-clinical · Mumbai
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile